More serious but less common risks can include: Gallbladder disease Pancreatitis Worsening of diabetic retinopathy in patients with diabetes Thyroid C-cell tumors observed in animal studies Certain conditions, medications, or risk factors may influence whether a healthcare provider thinks GLP-1s are appropriate for you, so women should review their full medical history with a qualified provider before starting therapy
In this guide, you will find: The dose ranges evaluated so far (112 mg weekly) How gradual titration influences outcomes and side-effect management Key distinctions between Retatrutide and other GLP-1/GIP agonists What upcoming data may suggest about its clinical and real-world potential Key Takeaways Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors to improve metabolism and reduce appetite
Using BPC-157 and TB-500 together in nasal spray form lets researchers study both peptides without shots
What the Data Shows The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide at 5, 10, or 15 mg weekly or placebo for 72 weeks (3)
5,13 Clinical trials in obesity and non-alcoholic fatty liver disease suggest that multi-strain probiotic formulations can modestly improve anthropometric measures, lipid profiles, and, in some studies, increase GLP-1 concentrations
The easily dissolvable powder also helps balance the gut microbiome, which can assist in reducing cravings and improving satiety, per the brand
